-
-
-
-
-
-
-
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
-
-
-
-
-
-
-
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
-
-
-
-
-
-
-
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
-
-
-
-
-
-
-
Unusual 11 Mid-Day Movers 9/8: (GTXI) (TLRD) (RPRX) Higher; (GEVO) (TSCO) (PIR) Lower
15,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

